2Chang L C,Haggstrom A Growth characteristics of Implications N,Drolet B A,et al. infantile hemangiomas: for management [J]. Pediatrics, 2008, 122(2) : 360-367.
3L 6 aut 6 -Labr t ze C,Dumas de la Roque E,Hu- biche T,et al.Propranolol for severe hemangiomas of infancy [J]. N Engl J Med,2008,358(24):2649-2651.
4Haggstrom AN, Drolet BA, Baselga E,et al. Prospec- tive study of infantile hemangiomas: clinical charac- teristics predicting complications and treatment [J]. Pediatrics, 2006,118(3): 882-887.
5Aehauer BM, Chang CJ,Vander Kam VM. Manage- ment of hemangioma of infancy:review of 245 pa- tients [J]. Plast Reconstr Surg,1997,99 (5): 1301-1308.
6Lanclells I. Treatment of hemangiamas in children[ J]. Skin Therapy Lett, 2001,6 (11):3-5.
7Frieden IJ,Drolet BA.Propranolol for infantile he- mangiomas: promise,peril,pathogenesis [J].Pediatrie Dermatology,2009,26(5):642-644.
9Sans V,De la Roque ED,Berge J,et al.Propranolol for severe infantile emangiomas:follow-up report[J]. Pe- diatrics,2009,124(3):e423-e431.
10Storch C H,Hoeger hemangiomas:insights nisms of action [J]. 269-274. P H. Propranolol for infantile into the molecular mecha- BrJ Dermatol,2010,163 (2) :.
